<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is an established risk factor for development of <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> and nonalcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease (NAFLD) </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to determine the prevalence and clinical correlates of these conditions in a large cohort of people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 939 participants, aged 61-76 years, from the Edinburgh Type 2 <z:mp ids='MP_0002055'>Diabetes</z:mp> Study (ET2DS)-a large, randomly selected population of people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-underwent liver ultrasonography </plain></SENT>
<SENT sid="3" pm="."><plain>Ultrasound gradings of <z:hpo ids='HP_0001397'>steatosis</z:hpo> were compared with magnetic resonance spectroscopy in a subgroup </plain></SENT>
<SENT sid="4" pm="."><plain>NAFLD was defined as <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> in the absence of a secondary cause (screened by questionnaire assessing alcohol and hepatotoxic medication use, plasma <z:hpo ids='HP_0012115'>hepatitis</z:hpo> serology, autoantibodies and ferritin, and record linkage to determine prior diagnoses of <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>Binary logistic regression was used to analyze independent associations of characteristics with NAFLD </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:hpo ids='HP_0001397'>Hepatic steatosis</z:hpo> was present in 56.9% of participants </plain></SENT>
<SENT sid="7" pm="."><plain>After excluding those with a secondary cause for <z:hpo ids='HP_0001397'>steatosis</z:hpo>, the prevalence of NAFLD in the study population was 42.6% </plain></SENT>
<SENT sid="8" pm="."><plain>Independent predictors of NAFLD were BMI, lesser duration of <z:mp ids='MP_0002055'>diabetes</z:mp>, HbA(1c), <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, and <z:chebi fb="0" ids="6801">metformin</z:chebi> use </plain></SENT>
<SENT sid="9" pm="."><plain>These remained unchanged after exclusion of participants with evidence of <z:hpo ids='HP_0001395'>hepatic fibrosis</z:hpo> from the group with no <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Prevalences of <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> and NAFLD were high in this unselected population of older people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, but lower than in studies in which ultrasound gradings were not compared with a gold standard </plain></SENT>
<SENT sid="11" pm="."><plain>Associations with features of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> could be used to target screening for this condition </plain></SENT>
</text></document>